Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard L Ward

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Vaccine|September 6, 2002
Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotavirusesAnthony H Choi, Monica M McNeal, Mitali Basu, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|May 14, 2009
Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based studyMartin Sénécal, Marc Brisson, Marc H Lebel, et al.
The Journal of Infectious Diseases|August 10, 2005
Development of candidate rotavirus vaccines derived from neonatal strains in IndiaRoger I Glass, Maharaj K Bhan, Pratima Ray, et al.
Pediatrics|November 4, 2008
Burden of rotavirus disease among children visiting pediatric emergency departments in Cincinnati, Ohio, and Oakland, California, in 1999-2000Eileen L Yee, Mary Allen Staat, Parvin Azimi, et al.
Vaccine|June 1, 2006
Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trialNita Bhandari, Pooja Sharma, Roger I Glass, et al.
Vaccine|March 22, 2002
The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvantAnthony H Choi, Monica M McNeal, Jason A Flint, et al.
Vaccine|April 20, 2006
Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infantsTimo Vesikari, H Fred Clark, Paul A Offit, et al.
Journal of Virology|April 28, 2006
Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidatesJohn L VanCott, Anne E Prada, Monica M McNeal, et al.
Infection and Immunity|June 24, 2003
Infectious agent and immune response characteristics of chronic enterocolitis in captive rhesus macaquesKarol Sestak, Christopher K Merritt, Juan Borda, et al.
The Pediatric Infectious Disease Journal|December 15, 2010
Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methodsMary Allen Staat, Marilyn A Rice, Stephanie Donauer, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Vaccine|September 6, 2002
Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotavirusesAnthony H Choi, Monica M McNeal, Mitali Basu, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|May 14, 2009
Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based studyMartin Sénécal, Marc Brisson, Marc H Lebel, et al.
The Journal of Infectious Diseases|August 10, 2005
Development of candidate rotavirus vaccines derived from neonatal strains in IndiaRoger I Glass, Maharaj K Bhan, Pratima Ray, et al.
Pediatrics|November 4, 2008
Burden of rotavirus disease among children visiting pediatric emergency departments in Cincinnati, Ohio, and Oakland, California, in 1999-2000Eileen L Yee, Mary Allen Staat, Parvin Azimi, et al.
Vaccine|June 1, 2006
Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trialNita Bhandari, Pooja Sharma, Roger I Glass, et al.
Vaccine|March 22, 2002
The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvantAnthony H Choi, Monica M McNeal, Jason A Flint, et al.
Vaccine|April 20, 2006
Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infantsTimo Vesikari, H Fred Clark, Paul A Offit, et al.
Journal of Virology|April 28, 2006
Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidatesJohn L VanCott, Anne E Prada, Monica M McNeal, et al.
Infection and Immunity|June 24, 2003
Infectious agent and immune response characteristics of chronic enterocolitis in captive rhesus macaquesKarol Sestak, Christopher K Merritt, Juan Borda, et al.
The Pediatric Infectious Disease Journal|December 15, 2010
Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methodsMary Allen Staat, Marilyn A Rice, Stephanie Donauer, et al.
Pageof 5